CLM296 is Theranib’s groundbreaking first-in-class ALDH1A3 inhibitor, designed to address critical challenges in cancer treatment. With its unique mechanism of action and unparalleled specificity, CLM296 represents a transformative step forward in oncology.
Improved Survival Rates: Tackling chemotherapy resistance and metastasis directly enhances survival outcomes for patients with aggressive cancers.
Personalized Treatment: Biomarker-driven diagnostics ensure CLM296 is administered to patients who will benefit most, maximizing its effectiveness and minimizing unnecessary treatments.
Wide Applicability: CLM296 has shown potential across multiple cancer types, including breast, lung, colorectal, prostate, and glioblastoma, addressing high unmet needs in oncology.
Combination Therapy Advantage: CLM296 amplifies the efficacy of existing therapies, making it an ideal candidate for integration into current treatment regimens.
Safer and More Tolerable: Preclinical studies indicate a favorable safety profile with minimal toxicity, improving patient quality of life during treatment.
Transformational Potential: As the first-in-class ALDH1A3 inhibitor, CLM296 represents a new approach to cancer care, providing hope for patients where standard treatments have failed.
Have questions about our groundbreaking cancer therapies or partnership opportunities? Reach out to Theranib Inc. and join us in advancing cancer care worldwide.